Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Germany offers cutting-edge treatments for Age-Related Macular Degeneration (AMD) including Lucentis and Eylea injections, and photodynamic therapy. These treatments help prevent vision loss and improve symptoms.
Germany's healthcare system is known for its high quality and efficiency. AMD patients may need regular follow-up appointments.